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Biodegradable elastic nanofibrous 
platforms with integrated flexible 
heaters for on-demand drug 
delivery
Ali Tamayol1,2,3, Alireza Hassani Najafabadi1,2,4, Pooria Mostafalu1,2,3, Ali K. Yetisen5, 
Mattia Commotto1,2, Musab Aldhahri6,7, Mohamed Shaaban Abdel-wahab6, Zeynab Izadi 
Najafabadi8, Shahrzad Latifi9, Mohsen Akbari1,2,3,10, Nasim Annabi1,2,11, Seok Hyun Yun5, 
Adnan Memic6, Mehmet R. Dokmeci1,2,3 & Ali Khademhosseini1,2,3,6,12
Delivery of drugs with controlled temporal profiles is essential for wound treatment and regenerative 
medicine applications. For example, bacterial infection is a key challenge in the treatment of chronic 
and deep wounds. Current treatment strategies are based on systemic administration of high doses 
of antibiotics, which result in side effects and drug resistance. On-demand delivery of drugs with 
controlled temporal profile is highly desirable. Here, we have developed thermally controllable, 
antibiotic-releasing nanofibrous sheets. Poly(glycerol sebacate)- poly(caprolactone) (PGS-PCL) blends 
were electrospun to form elastic polymeric sheets with fiber diameters ranging from 350 to 1100 nm 
and substrates with a tensile modulus of approximately 4-8 MPa. A bioresorbable metallic heater was 
patterned directly on the nanofibrous substrate for applying thermal stimulation to release antibiotics 
on-demand. In vitro studies confirmed the platform’s biocompatibility and biodegradability. The 
released antibiotics were potent against tested bacterial strains. These results may pave the path 
toward developing electronically controllable wound dressings that can deliver drugs with desired 
temporal patterns.
In many regenerative processes, different bioactive cues are involved at various stages of healing. One prominent 
challenge in many reconstructive and regenerative therapies is controlling bacterial infection, in particular in 
the treatment of chronic wounds and burns1. The skin is the primary protective barrier against environmental 
pathogens and if damaged bacterial risk factors increase significantly2–4. Some strains of pathogenic bacteria 
such as Pseudomonas aeruginosa and Staphylococcus aureus are detrimental to wound healing and if not properly 
managed can significantly increase the morbidity and mortality rate5, 6. Similarly, despite safety measures the rate 
of failure in implantation of surgical meshes due to infection is significant7.
Existing infection treatment strategies include oral and intravenous administration of antibiotics that can 
reach up to 2000 mg per dosage8. Such routes of administration can have side effects on healthy tissues or organs 
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and are of significant concern due to formation of antibiotic resistance9. One promising strategy for management 
of bacterial infection is based on localized delivery of antibiotics at a precise dosage only when necessary10. For 
instance, it was shown that the localized therapy resulted in fewer surgical site infections after dermatological 
surgery as compared to patients administered perioperative oral antibiotics8. In recent years, advances in drug 
delivery platforms and wound dressings have enabled the passive controlled release of active compounds11–14. 
For example, several wound dressings have been developed that use antibiotics or antiseptics (e.g., silver or 
iodine)15–17. While such platforms and wound dressings demonstrated sustained release of antibiotics, they 
often provide limited controllability on the release rate of drugs18, 19. Antiseptic agents in wound dressings may 
impair functions necessary for wound healing, thus they only should be released if necessary20. However, existing 
wound dressings are usually not capable of releasing these compounds on-demand. Thus, there is a clear need for 
advanced meshes that can be used in both implantable and topical applications for on-demand release of bioactive 
compounds including antibiotics. One possible solution for achieving this goal is to employ stimuli-responsive 
polymers which can respond to external stimulus for active drug release.
The fabrication of flexible electronics on non-conventional platforms has enabled the realization of systems 
that form conformal contact with non-flat surfaces (i.e., skin)21–25. Thus, integrated electrical systems can be used 
as a promising platform for applying the external stimulation required for triggering drug release19, 26, 27. For 
instance, electrical heaters can be powered via wires or wirelessly to generate heat as a safe external stimulation 
method. Here, we create an elastic nanofibrous mesh made of PGS-PCL containing PEGylated-chitosan based 
thermo-responsive drug nanocarriers. An integrated flexible heater was used to generate heat on-demand to 
trigger the drug release (Fig. 1). The heater was fabricated from various metals that can render the platform with 
improved biocompatiblilty and can be made fully biodegradable if required. The platform was used for controlled 
release of various antibiotics such as cefazolin and ceftriaxone encapsulated in nanoparticles. A microcontroller 
was used to tune the voltage throughout the conductive film to apply heat to the wound dressing. Upon stimu-
lation by the heating unit, these thermo-responsive nanoparticles released encapsulated antibiotics at a certain 
range of temperature (38–40 °C). This platform can open the way toward the realization of fully degradable smart 
surgical meshes.
Results and Discussion
The goal of this study was to develop a mesh-like platform that could be used in both internal and topical applica-
tions and could release drugs on-demand. In addition to biocompatibility and tunable degradability, such a plat-
form should have flexibility and elasticity comparable to native tissues. Recently, we have developed nanofibrous 
substrates for the fabrication of elastic electronics28. In addition to suturability, these nanofibrous meshes offer 
high surface area-to-volume ratio, which is important for effective drug release29. Thus, we fabricated PGS-PCL 
nanofibrous membranes using electrospinning (Fig. 2a–c). These meshes were highly stretchable and possessed 
extensibility of over 100% of their initial length (Figure S1).
To achieve on-demand drug release, thermo-responsive nanoparticles were synthesized from a 
PEGylated-chitosan blend. PEGylated-chitosan is biodegradable, biocompatible, non-toxic and immunocom-
patible; thus, it has been widely used in pharmaceutical fields30–32. PEGylated-chitosan has a controlled transition 
temperature and antibacterial characteristics as compared to other thermo-sensitive polymers31. This material 
goes through a sol-gel transition at the critical temperature of ~37 °C (Figure S2); details of material characteriza-
tion is provided in Supplementary Information (Figures S2, S3). This temperature is slightly higher than the skin 
temperature (32–36 °C)33.
Nanoparticles were fabricated by the emulsification of aqueous PEGylated-chitosan solution (1.0% w/v; 1 mL) 
in methylene chloride (1 mL) and genipin solution (5 mL of 0.05 mM) to rapidly form nanoparticles without 
agglomeration. The nanoparticle size distribution and morphology were determined using transmission electron 
microscopy (TEM), dynamic light scattering (DLS), as well as atomic force microscopy (AFM). The nanoparti-
cles had a mean diameter of 80 nm in solution with a narrow size distribution (Fig. 2d). The TEM images also 
confirmed the uniform size distribution determined using DLS (Fig. 2e). The difference in the DLS data could be 
Figure 1. The principle of operation of the drug delivery system and a typical fabricated bandage with 
integrated heater and electronics. Thermo-responsive drug nanocarriers were embedded within nanofibers of 
the engineered mesh and released their payload upon temperature increase induced by the integrated flexible 
heater. A typical fabricated bandage with the miniaturized control electronics is shown on the right.
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due to the swelling of drug carriers as the DLS measurements were performed in aqueous environment as com-
pared to TEM imaging which were conducted at dry state. It is known that the hydrogel-based particles possess 
high water uptake and rapid swelling, thus, the hydrated particles used in the DLS system were swollen31, 34, 35. In 
the present study, all the measurements were carried out when the equilibrium state was reached. TEM images 
indicated that the particles were spherical. These measurements were further verified by AFM, which showed 
uniform size distribution without aggregation (Figure S4). This is an important factor in achieving reproducible 
and predictable release profiles. The advantage of AFM data is that the particles are neither at the swollen state nor 
under vacuum. Thus, the obtained results are the closest to the actual working condition of the particles encapsu-
lated within nanofibers. The size distribution of the particles obtained from AFM and TEM images are also shown 
in Figure S4. The approximate size of the particles measured by TEM was around 60 nm, while the value for the 
images obtained from AFM was around 70 nm.
Nanofibrous meshes were fabricated by electrospinning of PGS-PCL prepolymer solution (20%, w/v) prepared 
at different ratios. The mechanical properties of the electrospun meshes such as their elastic modulus were tuned 
by changing the PGS:PCL ratio (Fig. 2f). In addition, PEGylated-chitosan nanoparticles were mixed with the 
prepolymer solution at the concentration of (15%, w/v) and were electrospun. The mechanical strength and stiff-
ness of hydrogels have been reported in the literature and are significantly lower than the polymeric substrate36. 
Thus, when PEGylated-chitosan particles were added to the polymeric network, weak points would have been 
generated throughout the polymeric network. Thus, the overall mechanical properties of the substrate could be 
reduced due to the presence of the nanocarriers. However, the incorporation of the nanoparticles within the size 
range used did not significantly change the elastic modulus of the nanofibrous mesh (Fig. 2f).
We have previously fabricated electrical circuitry and conductive patterns on nanofibrous meshes using screen 
printing and inkjet printing of conductive inks made of silver particles and carbon nanotubes25, 28. However, 
the low pattern substrate fidelity, toxicity and immune response against the materials used in development of 
these inks were a key limitation in their biomedical applications. In the present work, we used low temperature 
radio frequency (RF) sputtering that allowed the deposition of various metals onto the substrate. The RF sput-
tering was performed on the nanofibrous substrate, mounted onto a cooled sample holder, which was able to 
control the temperature of the sample during the deposition process. The temperature of the samples was kept 
lower than 25 °C during deposition, which was below the critical temperature of PEGylated-chitosan particles. 
Using this technique, we generated conductive patterns from various metals including silver, gold, zinc, and 
magnesium. The utilized deposition method allowed the penetration of metal into the substrate that improved 
pattern-substrate fidelity (Fig. 3a,b). We did not observe the detachment of the pattern from the substrate in SEM 
imaging. We also assessed the possibility of sustaining a stable temperature using heat generated by applying 
electrical voltage to fabricated patterns and measuring their surface temperature (Fig. 3c). It can be seen that the 
surface temperature was stable for up to 10 min. The fabricated conductive patterns were stretchable. Figure S5 
shows the variation of the electrical resistance of a typical conductive pattern sputtered on a nanofibrous substrate 
Figure 2. Fabrication of the elastic biodegradable nanofibrous drug delivery platform. (a) Schematic of the 
fabrication of the substrate by electrospinning (b,c) Representative SEM images of a typical nanofibrous 
substrate containing drug nanocarriers. (d) Size distribution of the generated particles in wet conditions 
measured by DLS. (e) TEM image of PEGylated chitosan nanoparticles which represented the spherical shape of 
nanoparticles and particles size. (f) Effects of nanocarriers on the Young’s modulus of the nanofibrous substrate 
containing 10% (w/w) of nanocarriers.
www.nature.com/scientificreports/
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versus the applied strain. The conductive patterns maintained a linear increase in resistance versus strain behavior 
for up to 20% strain.
Although degradability of PGS-PCL as a substrate for flexible electronics has been previously demonstrated, 
the fabricated conductive patterns were not resorbable in those cases28. The ability to generate patterns from zinc 
and magnesium enabled the present construct to be a fully degradable platform. To test the degradability of the 
engineered conductive patterns, an alkaline solution (2.5 mM of NaOH in PBS) was used. Alkaline solutions 
enhance the degradation rate and enable the investigation of degradability of the engineered constructs. Since 
the pH of the chronic wound environment is less than 937–39, we expect that the degradation rate of the conduc-
tive patterns to be similar. Determining the exact degradation profile at various pH values requires comprehen-
sive experiments which are beyond the scope of the present study. However, our experiments suggested a slow 
Figure 3. Characterization of the nanofibrous substrate containing nanocarriers and the engineered heater. 
(a,b) Representative images of a nanofibrous substrate with a biodegradable Zn heater deposited by RF 
sputtering. (c) Characterization of the zinc microheater, the resulting temperature as a function of applied 
voltage. (d) Degradation of zinc patterns over 24 days in aqueous solutions containing NaOH (2.5 mM). (e) 
Micrograph showing the hydrolysis of zinc patterns over 24 days. (f) Degradation of magnesium patterns over 
4 h in aqueous solutions containing 2.5 mM NaOH. (g) A representative SEM image of a nanofibrous substrate 
heated to 38 °C for 1 h confirming the stability of the membranes at that temperature. (h) A representative SEM 
image of nanofibrous substrate heated to 50 °C for 1 h, showing melted, decomposed and deformed state.
www.nature.com/scientificreports/
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degradation of zinc patterns at pH of 8.5 (Figure S6). The hydrolysis of zinc patterns and resulting degradation 
can be seen in the micrograph shown in Fig. 3d. The degradation rate of the patterns was material dependent. For 
instance, zinc patterns were present for over 20 days, while magnesium patterns degraded in less than one day 
(Fig. 3d–f). Electrical heaters were fabricated on the nanofibrous meshes as described above and voltage applied 
to the heater was varied to alter the mesh temperature. SEM images were taken from heated nanofibrous meshes 
to study the effect of temperature on the stability of nanofibrous meshes (Fig. 3g,h). Slight defects were observed 
in the fibers that were heated up to 38 °C (Fig. 3g), while the morphology of the nanofibers heated up to 50 °C 
was changed (Fig. 3h). The slight deformation in the microstructure might be due to swelling and deformation of 
the incorporated nanoparticles. Therefore, we expect that the stability of the fibers at temperatures close to body 
temperature does not allow sudden release of drug or nanoparticles from the mesh.
We evaluated the effectiveness of the platform for encapsulation and on-demand release of commercial antibi-
otics including cefazolin and ceftriaxone. Drug encapsulation efficiency of PEGylated-chitosan were investigated 
at different concentrations of drug (0.1–3.0% w/v) and polymer (0.1–1.0% w/v) (Tables S1, S2). Results indicated 
that increasing the encapsulation efficiency of ceftriaxone was a function of PEGylated-chitosan concentration 
in the solution to a maximum of 91% at 1% (w/v). A non-linear relationship was observed between the ratio of 
drug and PEGylated-chitosan concentrations and encapsulation efficiency. We observed the best encapsulation 
efficiency at ratio of 3:1 (w/w) drug to PEGyelated-chitosan. The encapsulation efficiency was ~83% by addition 
of 3% (w/v) of cefazolin and ~91% for 3% (w/v) of ceftriaxone. The encapsulation efficiency decreased to 75% and 
68% for 3.5% (w/v) aqueous solutions of cefazolin and ceftriaxone, respectively. This difference was perhaps due 
to the difference in the interaction between drugs and the polymer. Thus, maximum 3% (w/v) drug concentration 
was used throughout the experiments.
The capability of PEGylated-chitosan loaded PGS-PCL nanofibrous mesh to release drugs by different rates 
was assessed at different temperatures. Drug loaded nanoparticles were mixed with the PGS-PCL prepolymer 
solution (15% w/v) prior to electrospinning. To visualize the release from the nanofibrous meshes, we encapsu-
lated methylene blue into nanoparticles prior to the fabrication of electrospun meshes. The meshes were placed 
into different wells of a multiwell plate containing phosphate buffered saline (PBS) and different voltages were 
applied to create different surfaces temperatures. The volume of the solution during the test was kept constant 
and the evaporated solution was adjusted every 8–12 h by adding fresh solution. In addition, to prevent excessive 
evaporation the containers were covered with an impermeable lid. As shown in Fig. 4a, increasing the surface 
temperature increased the release rate of methylene blue from nanofibers, which in turn enhanced the color 
intensity of the surrounding liquid.
Similarly we assessed the release rate of cefazolin and ceftriaxone from the nanofibrous system. The solubility 
of the drug can potentially change by variations in temperature. However, the tested drugs are hydrophilic and 
are highly water soluble. Therefore, at the concentrations used, the solubility was not an issue and did not affect 
the release rate. Figure 4b,c indicates that about 40% of cefazolin was released from nanofibers during the first 2 
h, and around 98% of cefazolin was released after 24 h at 40 °C. However, for T = 20 °C less than 8% of cefazolin 
was released from nanofibers after 24 h, which could be attributed to transition temperature of the nanoparticles 
(Tcr~ 37 °C). In addition, no initial burst release was observed for samples and controls. The drug release profile of 
ceftriaxone was generally similar to cefazolin, but the difference between the concentration of the drug released 
over same temperature and time for both drugs could be attributed to the size of drug molecules and interaction 
between drug molecules and polymers. Since the transition temperature of the PEGylated-chitosan is ~37 °C, 
the sol to gel transition starts around 30 °C, which initiates the drug release and becomes completed ~ 40 °C 
(Figure S3). We also investigated the possibility of prohibiting the drug release on demand. Heat was applied 
in pulses/periods of 1 h while the heat application was stopped for another 1 hr. The drug release was stopped 
once the surface temperature was reduced (Fig. 4d). Thus, the nanofibrous mesh can be used for the delivery of 
antibiotics and drugs with a desired temporal pattern. Since the human skin temperature is around 33 °C, the fab-
ricated platform with a critical temperature of 37 °C can be implemented for topical applications. Thus, to prevent 
uncontrolled release of encapsulated drugs due to external temperature changes in topical applications, the plat-
form should be thermally insulated. However, for internal application, the synthesized thermo-responsive poly-
mer could be co-polymerized with other biocompatible monomers to increase its critical temperature. We also 
assessed the functionality and effectiveness of the released drug after thermal stimulation. Nanofibrous meshes 
containing nanoparticles with and without cefazolin were fabricated as described before. To evaluate the effec-
tiveness of the released antibiotics, zone of inhibition and number of colony forming units (CFU) methods were 
employed. Gram positive and Gram negative bacteria such as S. aureus and E. coli were cultured on the agar plates 
and samples of ~1.5 cm in diameter were placed on the cultured plates. The surface temperature was increased to 
38 °C using the integrated flexible heaters and the zone of inhibition was determined after 24 h of culture (Fig. 4e). 
The sample containing antibiotics had a noticeable zone of inhibition (~10 mm), which was not observed in 
the heated sample without antibiotics and the sample containing antibiotics without a heater (Fig. 4e). We also 
assessed the number of CFUs in a bacterial culture. Circular samples (15 mm in diameter) were placed in a bac-
terial culture (10 mL) and were heated at a constant rate to increase the surface temperature to 38 °C. After 24 h of 
culture, the number of CFUs was significantly reduced (Fig. 4f,g and Table S4).
The biocompatibity of the engineered nanofibrous meshes was assessed by culturing human keratinocytes 
on the meshes and monitoring their metabolic activity and morphology. The metabolic activity of cells cultured 
on the surface of the mesh containing thermo-sensitive particles and drug carriers was measured using Presto 
Blue assay. No significant difference was observed between the cells cultured on meshes with and without nano-
particles. However, the meshes that included silver-based heaters showed lower metabolic activity (Fig. 4h). This 
reduction was possibly due to the inhibitory effect of silver on keratinocytes growth40. Staining against F-actin 
showed normal cellular morphology on the electrospun meshes (Fig. 4i).
www.nature.com/scientificreports/
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Nanofibrous meshes have been used as scaffolds for skin growth in treating burns and wounds. The mechan-
ical properties of PGS-PCL nanofibrous meshes including their elasticity and elastic modulus are similar to the 
values for skin28. Thus, in addition to topical applications as shown in Fig. 1, the suturability of the engineered 
nanofibrous mesh allows its use as a scaffold for cell growth as well as closing deep wounds.
Figure 4. Characterization of the release profile and biocompatibility of the engineered platform. (a) Effect of 
temperature on the intensity of the methylene blue release from the nanofibrous platform. (b) The spectrum 
of release rate of cefazolin from the nanofibrous drug delivery system at different temperatures. (c) Effect 
of temperature on the interfacial release rate of ceftriaxone from the nanofibrous drug delivery system. (d) 
Cyclic thermal stimulation at different temperatures for on-demand release of cefazolin. (e) Assessment of 
the effectiveness of the released drug against bacterial culture; occurrence of a clear inhibition zone around 
the mesh containing cefazolin at 38 °C (i) in comparison to the mesh without cefazolin (ii) and the mesh 
containing cefazolin without heater after 12 h (iii). (f,g) Effect of the released antibiotics on the number of 
CFUs in a bacteria solution after 24 h of culture; ceftriaxone against E. coli and cefazoline against S. areus. (h) 
Metabolic activity of human keratinocytes cultured in contact with the nanofibrous substrate with and without 
nanoparticles and the flexible heater (***p < 0.001). (i) Immunostaining against F-actin and cell nuclei (DAPI) 
confirming the normal morphology of the cells cultured in contact with the nanofibrous substrate.
www.nature.com/scientificreports/
7SCIENTIfIC RepoRTs | 7: 9220  | DOI:10.1038/s41598-017-04749-8
Conclusions
A nanofibrous elastic mesh was engineered to carry stimuli-responsive drug carriers and could be used as a sub-
strate for the fabrication of flexible heaters. Thermo-responsive particles of PEGylated-chitosan were fabricated 
with a critical temperature ~37 °C. The nanoparticles were embedded within the nanofibrous meshes and were 
loaded with antibiotics. A flexible heater was integrated into the platform to allow on-demand release of drugs. 
The engineered platform was flexible, elastic and could form conformal contact with native tissues. The platform 
could be either used as a topical patch or possibly as an implantable scaffold for wound closure. In the latter case, 
heaters could be fabricated from biocompatible and bioresorbable metals including zinc and magnesium, where 
their degradation rate could be tuned. The drug release rate was proportional to the applied voltage that gener-
ated heat and altered the surface temperature. The effectiveness of released antibiotics was assessed against the 
culture of different bacterial strains inhibiting their growth. The engineered platform can be further developed for 
engineering smart surgical meshes, tissue engineering scaffolds, and wound dressings, which can release drugs 
in response to external stimuli on-demand. Also, other stimuli-responsive materials can be incorporated into the 
platform to allow independent release of multiple drugs.
Experimental Section
Materials. Chitosan, medium viscosities of 200–800 cps, acetic acid, poly(ethylene glycol) monomethyl ether 
(mPEG) (MW 2000), sodium dodecylsulfate (SDS), anhydrous tetrahydrofuran (THF), genipin (GP), sodium 
hydroxide (NaOH), anhydrous N,N-dimethylformamide (DMF), oxalyl chloride, poly ɛ-caprolactone (PCL) with 
average molecular weight 80000), glacial acetic acid, sodium hydride (NaH), anhydrous pyridine, acetonitrile, 
and methanol were purchased from Sigma-Aldrich (St. Louis, MO, USA). Anhydrous chloroform and ethanol 
were purchased from Fisher Scientific (USA). Cell culture reagents including Dulbecco’s modified Eagle medium 
(DMEM), 0.05% trypsin-EDTA (1X), fetal bovine serum (FBS), and Penicillin/Streptomycin were purchased 
from Invitrogen (Carlsbad, CA, USA). PrestoBlue® Assay and Live/Dead Cell Viability Kit were obtained from 
Life Technologies. Cefazolin sodium salt (≥98% purity) was obtained from Fluka (Buchs, Switzerland).
Synthesis of PGS. Synthesis of PGS (MW 12,000) was performed as described before41. Briefly, PGS was 
prepared by polycondensation of sebacic acid and glycerol under inert gas atmosphere at 120 °C for at least 24 h. 
The pressure was reduced to 40 mtorr over 48 h to prepare PGS.
Preparation of PEGylated-chitosan. Chitosan grafted poly(ethylene glycol) monomethyl ether 
(mPEG) was prepared as described previously42, 43. Briefly, sodium dodecylsulfate (SDS) solution in water was 
mixed with the chitosan and the suspension mixed for 2 h at room temperature. The precipitation was filtered 
off, washed with DI water three times, and freeze-dried to obtain SDS/chitosan. Then, oxalyl chloride was mixed 
with 10-fold of SDS/chitosan weight (0.1 g) in anhydrous pyridine (50 mL). The reaction was continued at room 
temperature over 30 min under pre dried inert gas atmosphere. Consequently, the products were cooled down 
and freeze dried to extract chlorinated-SDS/chitosan. Then, mPEG (mPEG, 4 g) was activated by adding NaH 
(10 mg) into 50 mL of THF solution to form OH-PEG-OCH3. The reaction was carried out under continuous 
stirring at 60 °C for 2 h under inert gas atmosphere. Then, prepared chlorinated-SDS/chitosan (60 mg) was added 
slowly to the reaction and mixed for one day, under the same condition. Finally, the products were cooled down 
to room temperature and precipitated in methanol. The percipients were then washed and freeze dried. The 
SDS protection was removed by adding 15% (w/v) tris (hydroxyl methyl) amino methane aqueous solution and 
adjusting the pH to 8 using HCl (5.0 M) at room temperature. The precipitates were then freeze-dried to obtain 
chitosan-graft-PEG (PEGylated chitosan).
Characterization of polymer synthesis. Proton-nuclear magnetic resonance (1 H NMR) was conducted 
on Bruker Avance 800 MHz NMR spectrometer to analyze the chemical structure and degree of substitution on 
mPEG to chitosan. Briefly, 10–20 mg of each sample was dissolved in deuterium oxide (D2O) containing 0.5 M 
DCl/D2O or dimethyl sulfoxide (DMSO) as a solvent. 1H-nmr data of chitosan and PEGylated chitosan was 
obtained as follows: the chemical shifts of chitosan and PEGylated chitosan are: 1.85 (s, 3 H, -C(O)OCH3), 2.57 (s, 
3H-CH3), 3.59 (s, 1 H, H2), 3.97–4.12 (m, 4 H, H5), 4.14–4.51 (m, 5 H, H6, H3, H4), 5.30 (s, 1 H, H1). PEGylated 
chitosan: 1.85(s, 3 H, -CH3 in acetamide of chitosan), 2.85 (s, 1 H, H2 in chitosan), 3.3 (s, 3 H, -OCH3), 3.2–3.8 
ppm (m, nH, PEG-OCH2CH2O and, H3 and H6 in chitosan (pyranose ring).
Fourier Transform Infrared Spectroscopy (FT-IR). Fourier transform infrared spectroscopy (FT-IR) 
was carried out using a spectrometer (Shimadzu 8400 S FTIR, Osaka, Japan). For FTIR spectra analysis, a dried 
sample (10 mg) was mixed with dry KBr (500 mg). The mixture was pressed to form disks using a macro KBr die 
kit. The solid pellet was scanned at 4 cm−1 in FTIR instrument.
Nanoparticle preparation. Nanoparticles were prepared using emulsification ionic gelation. Briefly, 
PEGylated-chitosan was dissolved in double distilled water (1.0% w/v; 1 mL). Then, the polymer solution was 
added to 1 mL of methylene chloride containing 20% (w/v) poly vinyl alcohol as surfactant and sonicated for 
1 min over ice bath. Subsequently, the emulsion was stirred and 5 mL of aqueous genipin solution (0.05 mM) was 
added drop-wise to the previously prepared emulsion. The emulsion was stirred (1000 rpm) at room temperature 
for ~12 h to crosslink the nanoparticles and evaporation of methylene chloride. Drug-loaded nanoparticles were 
prepared by dissolving predetermined amount of drug in aqueous polymer solution, and the synthesis procedure 
was performed as described above. Crosslinked nanoparticles were then separated from the solution by ultracen-
trifugation (SIGMA 3–16 K Centrifuge, UK) at 20,000 g and were washed twice with DI water to remove excess 
unreacted polymer, crosslinker, and the free drug. Finally, nanoparticles were freeze dried and stored at 4 °C until 
further use.
www.nature.com/scientificreports/
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Nanoparticle Characterization. Nanoparticle size was determined by three different methods including 
AFM in the tapping mode, DLS, and TEM. Silicon tapping tips (TESP, VEECO) were used to perform AFM (JPK, 
Nanowizard 2, JPK Instruments, Germany). Samples were prepared by dispersing nanoparticles in DI water at 
1 mg/ml concentration and placing one drop on the polyethylene imine coated glass cover slip then air dried. 
Samples imaging was conducted by using Nano-scope III (Digital Instrument/VEECO). TEM imaging of nano-
particles was performed following negative staining with uranyl acetate. Samples were prepared similar to AFM 
test, but were placed on formvar-coated copper grids (Ted Pella, Inc., Redding, CA) and were tested using a TEM 
instrument (TEM, Philips/FEI, Inc., NY). The diameters of about fifty nanoparticles in the TEM images were 
calculated by using a digital caliper manually. The nanoparticle size was also measured by DLS using a Malvern 
Zetasizer Nano ZS (Malvern Instruments, UK) at a fixed scattering angle (90°).
Drug loading and encapsulation efficiency. The drug loading (DL, w/w%) of nanoparticles was meas-
ure by dissolving freeze dried nanoparticles in water followed by determining their drug content using a HPLC 
system (Agilent Technologies Inc, 1200, CA, USA) equipped with a UV detector (Agilent Technologies Inc, 1200) 
and reversed phase column (ODS C18, 5 µm, 4.6 mm × 250 mm, Dikma, China). The mobile phase contained a 
mixture of acetonitrile and monobasic sodium phosphate buffer with the ratio of 17:83 (v/v%) with a flow rate of 
1 mL/min. The signal was measured at 254 nm to determine the drug concentration. The DL of the nanoparticles 
was then calculated44:
DL% Total mass of drug extracted from freeze dried nanoparticles
Total mass of freeze dried nanoparticles
100
(1)
= ×
The concentration of drug in the aqueous phase was determined using HPLC as described previously. 
Encapsulation efficiency (EE) was reported as:
= ×EE% Total amount of drug inside nanoparticles
Total amount of drug in the initial solution
100
(2)
It should be noted that EE shows the ratio of the actual encapsulated drug over the intended value, while DL is 
referring to the actual encapsulated drug quantity with respect to the dry weight of nanoparticles.
Drug release from nanofibrous meshes with integrated heaters. The device with the heater was 
placed on the surface of 1.5 ml of freshly prepared PBS and a tiny magnetic stirrer bar was placed in PBS media, 
and different electrical voltage was applied to the conductive pattern to generate heat. The drug released during 
different voltages, temperature and time was measured by HPLC based on the method previously mentioned45, 46. 
The surface temperature of the device measured by Welch Allyn 105801 Caretemp Touch Free Infrared 
Thermometer. According to the manufacturer information the accuracy of the system is ±0.5 °C.
Electrospinning. PGS and PCL were dissolved at ratios ranging from 1:1–1:5 in anhydrous chloroform: 
ethanol (9:1, v/v) mixture, where the total polymer concentration was kept constant at 20% (w/v). An electrical 
voltage of 19.5 kV over a distance of 15 cm was applied and the prepolymer mixture flow rate was set at 1.5 mL/h 
during electrospinning. The prepolymer mixture was spun to obtain a nanofibrous sheet (~170 μm thickness). 
The electrospun sheet was dried using a fan for 12 h with airflow rate of 12 m3 h−1 to remove any residual solvent 
prior to use. Nanoparticles-loaded nanofibers were prepared by dissolving predetermined amount of nanopar-
ticles in pre polymer solution, ultrasound to make it homogeneous and the electrospinning was performed as 
mentioned above.
Degradation. Patterned electrospun sheets were placed in polystyrene Petri dishes containing 2.5 × 10−3 
M of NaOH in PBS solution (5 mL). Samples were kept in NaOH solution at 37 °C. A digital camera was used to 
capture the photographs of the nanofibrous sheets.
Scanning Electron Microscopy (SEM). Dried electrospun samples were mounted on aluminum stubs 
using copper adhesive tape. The SEM images of the gold coated samples were acquired using a JEOL JSM 7600 F 
(10 KV) to determine the microarchitecture of the electrospun nanofibrous sheets.
X-ray Diffraction (XRD). X-ray diffraction data of the coated sheets were acquired using Ultima-IV diffrac-
tometer (Rigaku, Japan) (Cu Kα radiation λ = 1.5418 Å at 40 kV accelerating voltage and 30 mA) with parallel 
beam geometry and a multipurpose thin film attachment. For all nanofibrous sheets, the XRD patterns were 
recorded in theta-2theta, grazing incidence angles of 4° to 8°, 0.05° increment size and 2 s count time per step.
Electrically conductive pattern fabrication and testing. Conductive patterns were fabricated from 
Zn/Mg/Ag using radio frequency (RF) magnetron sputtering (DC/RF Magnetron Sputter System, Syskey 
Technologies, Taiwan). Electrospun sheets were covered with a shadow mask, which was prepared by cutting a 
transparent sticker sheet using a laser engraver (Versalaser, VLS2.30). High purity targets of Zn/Mg/Ag (3.0 × 0.6 
in) were used. To prepare nanocrystalline Zn/Mg/Ag thin films, plasma was generated inside a chamber using 
argon gas with a flow rate of 20 sccm at RF power of 100 W while the base pressure and operating pressure were 
1 × 10−6 and 5 × 10−3 torr. The substrate rotation, target-substrate distance and deposition time were 15 rpm, 
14 cm and 1000 s, respectively with an approximately 500 nm film thickness that was measured using a surface 
profiler (DektakXT, Bruker, Germany). The thickness of the film was controlled by increasing or decreasing the 
deposition time. Finally, the shadow masks were removed from the sheets leaving the patterned electrical circuit 
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on the electrospun sheets. The coated sheets were subsequently used for electrical conductivity measurements 
using a multimeter.
Bacterial study. A wide range of bacterial strains were used for the experiments to verify the effectiveness 
of the release antibiotics: Escherichia coli, Pseudomonas fluorescens, Salmonella typhimurium, Vibrio parahaemo-
lyticus, Listeria monocytogenes, Bacillus megaterium, Bacillus cereus, Staphylococcus aureus, Lactobacillus plan-
tarum, Lactobacillus brevis, and Lactobacillus bulgaricus. The bacteria were inoculated and incubated in an air 
bath shaker (37 °C, 130 rpm) for 12 h until the culture entered the exponential period of growth. Bacteria with 
the concentration of ~1 × 105 CFU/mL were cultured for zone of inhibition and colony forming unit counting 
experiments. To investigate the application of device on bacterial, the device was placed on the surface of cultured 
bacteria, and different electrical voltages were applied to the conductive pattern to generate heat. A blank control 
sample without antibiotics was prepared for comparison. All the plates were incubated at approximately 34 °C for 
an appropriate time. Finally, the plates were taken out and the inhibition zone and number of remaining colonies 
were calculated.
Cell studies. Keratinocytes were cultured in a DMEM-based medium containing 10% FBS and 1% penicil-
lin/streptomycin. For cytotoxicity assessment, circular samples (1 cm in diameter) were prepared and placed at 
the bottom of 24-well polystyrene plates. Then, cells were resuspened in culture media at the concentration of 
1 × 107 cells/mL and 5,000 cells were seeded on the samples. The samples were incubated for 1 hr to allow cells to 
attach and then 300 µL of culture medium was added to each well. Cellular metabolic activity was measured using 
PrestoBlue® assay following manufacturer protocol on days 1, 3 and 7 and the assay results were measured using 
a BioTek UV/vis Synnergy 2 microplate reader.
Statistical analysis. Data from continuous parameters are expressed as means ± standard deviation (SD) 
of measurements (*p < 0.05, **p < 0.01 and ***p < 0.001) and were compared using one-way ANOVA testing 
in GraphPad Prism 6.
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